Debiopharm Group
Europe, Vaud, Switzerland, Lausanne
Description
Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug.
Investor Profile
Debiopharm Group has made 24 investments, with 1 in the past 12 months and 58% as lead.
Stage Focus
- Series Unknown (25%)
- Series A (17%)
- Seed (17%)
- Series B (13%)
- Private Equity (4%)
- Series D (4%)
- Series C (4%)
- Corporate Round (4%)
- Debt Financing (4%)
- Undisclosed (4%)
Country Focus
- Switzerland (58%)
- United States (21%)
- France (8%)
- The Netherlands (4%)
- Canada (4%)
Industry Focus
- Biotechnology
- Health Diagnostics
- Genetics
- Health Care
- Pharmaceutical
- Medical Device
- Medical
- Artificial Intelligence (Ai)
- Corporate Training
- Edtech
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
